Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations initially responds well to tyrosine kinase inhibitors (TKIs).
• Acquired T790M mutation is a common mechanism of resistance to first and second-generation TKIs in NSCLC.
• Understanding resistance mechanisms is crucial for developing effective, next-generation therapies.

Purpose of the Study:

• To prospectively investigate the correlation between initial EGFR mutational status and the acquisition of T790M resistance mutations in NSCLC patients.
• To explore the molecular basis of T790M acquisition using computational methods.

Main Methods:

• Prospective recruitment of 68 metastatic EGFR-mutated NSCLC patients progressing on TKI therapy.
• Liquid biopsy for detecting acquired T790M mutations post-treatment.
• Attribute ranking to identify factors associated with T790M acquisition.
• Computational studies to assess EGFR mutation stability.

Main Results:

• Initial EGFR mutational type was identified as a significant factor correlating with T790M acquisition.
• The EGFR delE746_A750 mutation showed lower stability around residue T790 compared to delS752_I759 and L858R.
• Patients with delE746_A750 were more prone to acquiring the T790M mutation.

Conclusions:

• The specific type of initial EGFR mutation impacts the likelihood of developing T790M-mediated resistance in NSCLC.
• Computational findings support clinical observations, highlighting the role of mutation stability.
• These insights are vital for developing novel, mutation-specific TKIs to overcome acquired resistance.